美通社

2024-09-09 20:06

Frost & Sullivan grants the Global Targeted Molecular Fluorescent Tracer R&D Leadership Award to Nanjing Nuoyuan Medical Devices Co., Ltd.

SHANGHAI, Sept. 9, 2024 /PRNewswire/ -- Frost & Sullivan is pleased to announce that the 18th Growth Innovation Leadership (GIL) Summit and the 3rd New Investment Event (NIE 2024), was held in Shanghai from August 27 to 30, 2024, co-hosted by LeadLeo.

Based on research and analysis of the global targeted molecular fluorescent tracer market, as well as studies and evaluations of relevant companies in the industry, Frost & Sullivan has awarded Nanjing Nuoyuan Medical Devices Co., Ltd. the Global Targeted Molecular Fluorescent Tracer R&D Leadership Award at the GIL Summit and NIE 2024. Mr. Aroop Zutshi, the Global Managing Partner and Executive Board Member of Frost & Sullivan, and Professor Yu Wang, the Chairman of Chinese Foundation for Hepatitis Prevention and Control and the Former Director General of Chinese Center for Disease Control and Prevention presented this award to Mr. Huiming Cai, Chairman and President of Nanjing Nuoyuan Medical Devices Co., Ltd.

Frost & Sullivan grants Nanjing Nuoyuan Medical Devices Co., Ltd. the "GLOBAL TARGETED MOLECULAR FLUORESCENT TRACER R&D LEADERSHIP AWARD"

Nuliferay aims to become a leader in precision medical technology

Nanjing Nuoyuan Medical Devices Co., Ltd. (Nuliferay) is a Chinese national high-tech enterprise integrating R&D, production, and sales of high-end medical devices and innovative targeted probes. The company has established an innovative model of "dual-track of medicine and equipment" development to provide full-chain solutions for precise oncology diagnosis and treatment. Nuliferay possesses ongoing innovation capabilities, develops multiple series of internationally advanced medical devices and contrast agents, and focuses on core technologies such as molecular fluorescence, Raman spectroscopy, artificial intelligence, and AI-assisted drug design. The company aims to become a leader in precision medical technology.

Under the "dual-track" development model, Nuliferay is developing innovative targeted fluorescence probe products

Nuliferay has developed multiple high-end fluorescence endoscopes, including surgical fluorescence imaging systems, 4K endoscopic fluorescence imaging systems, and the innovative "4K 3D endoscopic fluorescence imaging system." Additionally, they are working on the "AI-assisted Raman spectroscopy molecular fluorescence multi-modal navigation system" as part of a major Chinese national research project.

Nuliferay's "dual-track" strategy involves strengthening endoscope device technology while also advancing research and clinical application of molecular targeted probes associated with fluorescence endoscopes. Currently, the company is developing a series of innovative targeted fluorescent probe products. The related research achievements have been rapidly transformed and published in authoritative journals such as Cell Reports Physical Science (a sub-journal of Cell), Biosensors and Bioelectronics, Sensors and Actuators B-Chemical, and Chinese Journal of Academic Radiology. The company holds nearly twenty patents related to the structures, clinical applications, and impurities, establishing a solid technical barrier for subsequent development and application. With the advancements in endoscopic equipment and molecular targeted fluorescent probes, it is expected to further enhance the precision of oncological surgeries at the molecular level.

Nuliferay's targeted fluorescent probes is revolutionizing the navigation technology in fluorescence-guided surgery, and creating a path to international markets

Nuliferay is committed to leading the innovation process of China's medical endoscopy industry. Since its establishment in 2011, the company has undertaken more than ten national and provincial key research projects, including the "National 13th Five-Year Plan Key Research and Development Program," "National Major Scientific Research Instrument Development Project," "National Ministry of Industry and Information Technology's Artificial Intelligence Medical Device Innovation Task Unveiling," and "Jiangsu Province Key Core Technology Research Project." In 2023, Nuliferay was recognized as a "Specialized, Refined, Differentiated, and Innovative" enterprise in Jiangsu Province by the Jiangsu Provincial Department of Industry and Information Technology.

Nuliferay's series of targeted fluorescence probe products are aimed at multiple typical tumor receptors, significantly improving the precision and efficacy of tumor treatment and reducing false-positive rates. The company's research pipeline includes six series of products: folate receptor (FR), epidermal growth factor receptor (EGFR), mesenchymal-epithelial transition factor (cMET), vascular endothelial growth factor receptor (VEGFR), passive targeting broad-spectrum types, and neural imaging types. Nuliferay is also promoting the international market expansion of its best-in-class folate receptor (FRα) targeted probe NY-FR-07.

About Frost & Sullivan's Global Leadership Award

The Frost & Sullivan Global Leadership Award recognizes enterprises' outstanding performance and exceptional achievements in areas such as technology innovation, market potential, customer service, branding, and others. The Frost & Sullivan team nominated a group of competitive and excellent enterprises through methods including in-depth interviews, industry analysis, and secondary research. An independent judging panel, made up of third-party investment and financing experts, financial experts, bankers, and renowned listed company entrepreneurs, conducted rigorous evaluations of the nominated enterprises and decided to grant the 2024 Global Targeted Molecular Fluorescent Tracer R&D Leadership Award to Nanjing Nuoyuan Medical Devices Co., Ltd.

Media Contact
Contact: Qian Li
Company Name: Frost & Sullivan
Website: http://www.frostchina.com
Email: qian.li@frostchina.com 

source: Frost & Sullivan

【你點睇】卓林普經優才計劃成為香港居民,桌總冀當局放寬16歲以下青少年進入桌球室限制助年輕人接觸桌球,你是否認同?► 立即投票

人氣文章
最近7天
1
神州經脈 | PMI遜預期,滬指全年止跌回升,人幣年度貶幅擴
2
高息定存 | 工銀亞洲推3個月5厘息搶新客,招商永隆推快閃優惠
3
回顧展望-新股復燃 | 政策市激發IPO 惟六成新股破發損行情
4
港股 | 蕭猷華:恒指春節前可挑戰21500點
5
高息定存 | 一周高息合集,銀行年尾搶資金,大眾3個月3.6厘
6
藍圖2.0 | 旅遊發展藍圖2.0提四大策略,推特色項目智慧旅遊並開拓客源
7
微盟 | 炒完微信小店,微盟(2013)遭三名主要股東急沽持股套現
8
回顧展望-人幣走貶 | 關稅殺到,先貶為敬,人幣明年勢見7.5
9
回顧展望-A股自強 | 憧憬國策利好,機構對明年股市走勢樂觀
10
奧特曼 | 內地玩具商布魯可招股入場費1.8萬元,四基投認購
1
高息定存 | 滙豐3個月港元存息高達3.8厘,6個月3.55厘
2
高息定存 | 一周高息合集,大新3個月最高4.1厘,華僑及信銀國際見4厘
3
高息定存 | 華僑推3個月快閃達4厘,信銀國際全線升3個月存息
4
高息定存 | 銀行高息搶存,東亞上調3個月定存息至3.9厘,花旗加至3.7厘
5
局長換人 | 國務院:免去林世雄、楊潤雄局長職務,任命陳美寶、羅淑佩接任(楊潤雄facebook回應)
6
傾力救市 | 華爾街大行預計中國明年降息幅度將達十年來最大
7
建銀國際料明年恒指先低後高,波動區間18000至23000點
8
高息定存 | 建行亞洲上調3個月存息至3.85厘,富邦3.8厘
9
港股 | 蕭猷華:關注中央經濟工作會議,美團股價落後
10
高息定存 | 華僑銀行208日定存年息高達3.8厘
11
基建債券 | 認購額178.5億首未足額,發言人:受減息步伐影響
12
神州經脈 | 政治局會議定調明年貨幣政策適度寬鬆,CPI遜預期
13
新股 |【FOCUS】毛戈平膺「凍資王」,驚艷之後魅力臨考
14
詹培忠父子涉隱瞞秘密「買殼」串謀欺詐罪成
15
神州經脈 | 回購增持貸細則調整,13美國軍工企業遭反制
16
神州經脈 | 11月進出口數據降溫,貨幣政策轉向股匯齊漲
17
專訪|林本利系列專訪逢周五登場,股市篇:勿驚美股調整,港股那些可以放心買那些勿沾手(有片)
18
專訪|林本利系列專訪一連三個周五登場,樓市篇:中原指數長線重返180,買樓勿買新樓(有片)
19
特首述職|習近平讚揚李家超務實進取,中央全力支持帶領各界改革
20
滙控 | 擬推改革削減成本,股價再創17年新高,聖誕鐘真係要買滙豐?
21
神州經脈 | 特別國債或發3萬億,滬指逼近三千四,日外相訪華
22
南港島線西段擬高架行走,陳美寶:成本可較重鐵少四成
23
資源有限窒礙中小企轉型? 營商生態圈助你開拓無限商機!
24
高息定存 | 一周高息合集,華僑1個月定存4厘208日3.8厘
25
中經會 | 明年提高財政赤字率,適時降準降息,穩住樓市股市
26
居屋2024 | 新一期居屋攪珠結果出爐,預計最快明年第二季揀樓
27
2025年環球經濟與輪證投資前瞻
28
利率波動難測 如何以債券策略爭取「財息兼收」?
29
神州經脈 | 工業利潤降幅收窄,低空經濟發展司成立,滬指全周升
30
【穩醣趨勢: 揀無糖飲品、原型食物,戒澱粉質係咪就得? 】
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【etnet30周年連環賞】睇住賞Moon-River RELOVE 蛋白酵素去漬抑菌手洗精 (價值HK$188)

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

貨幣攻略

大國博弈

回顧24 展望25

說說心理話

聖誕新年特輯

Watche Trends 2024

北上食買玩

Artcation

秋冬養生食療

消委會報告

山今養生智慧

輕鬆護老